ARDS dividend history
Aridis Pharmaceuticals Inc. (ARDS) dividend declarations and ex-dividend dates - real-time wire coverage of every payout disclosure.
Recent dividend items
- Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business UpdateTop-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2022. Third Quarter Highlights Closed enrollment in the Company's Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022.Continued e
- Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business UpdateMultiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., Aug. 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2022. Second Quarter Highlights Continued enrollment in the Company's Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis remains on track to report top-line data from this study in 2H 2022.Continued enrollment in the Company's Phase 2a study of AR-501 targeting cy
- Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business UpdateMultiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., May 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2022. First Quarter Highlights Continued enrollment in the Company's Phase 2a study of AR-501 targeting cystic fibrosis (CF), conducted in collaboration with funding support from the CF Foundation. The top-line data from this CF study is now expected in 2H 2022.Continued enrollment in the Company's Phase 3 study eval
- Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business UpdateAwarded funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 LOS GATOS, Calif., March 31, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights Continued enrollment in the Company's Phase 2a study of AR-501 targeting cystic fibrosis (CF), conducted in collaboration with the funding support from the C